Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma Mar

Gilead Sciences

Gilead study resurrects HIV eradication hope

Intends to start human trials of its improved bNAb candidate

- PMLiVE

Bad news for Portola as CHMP considers Factor Xa drugs

The committee are ‘unlikely’ to adopt a positive opinion for betrixaban

- PMLiVE

Gilead’s triple HIV drug approval prompts GSK lawsuit

ViiV claims bictegravir infringes its patent estate

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

- PMLiVE

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

Swiss biopharma says it will re-file Raxone for the licence extension

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

- PMLiVE

ViiV starts trial of HIV-preventing injections for women

Cabotegravir could provide a new way for women to protect themselves

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

- PMLiVE

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’ and ‘durable’ viral suppression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links